rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    EWTX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Edgewise Therapeutics CFO Michael Nofi sells $201,786 in shares
      Nov 11Investing.comEWTX
      Edgewise Therapeutics stock hits all-time high of 48.53 USD
      Nov 9Investing.comEWTX
      Why Edgewise Therapeutics Stock Is In Focus After Phase 3 Filing For Heart Drug

      Edgewise Therapeutics reported net income of US$1,166.15 million in Q3 2026 and held a favorable End-of-Phase 2 meeting with the FDA that enabled submission of the STRATUS-HCM Phase 3 protocol for EDG-7500 in hypertrophic cardiomyopathy. The planned STRATUS-HCM program uses an echo independent, investigator guided dose escalation design across both obstructive and nonobstructive hypertrophic cardiomyopathy within a single global master protocol, which reflects how Edgewise Therapeutics is...

      Nov 7Yahoo FinanceEWTX
      Edgewise submits phase 3 protocol for heart drug EDG-7500
      Nov 5Investing.comEWTX
      Edgewise earnings ahead as Phase III start for EDG-7500 looms
      Nov 4Investing.comEWTX
      Edgewise Therapeutics (EWTX) Gets a Buy from RBC Capital

      Tipranks Press Release.

      Oct 28The Globe and MailEWTX
      Edgewise Therapeutics' Investors Focused on Upcoming Phase 3 Design for '7500 in Hypertrophic Cardiomyopathy, RBC Says
      Oct 27Yahoo FinanceEWTX
      William Blar Initiates Coverage on Edgewise Therapeutics With Outperform Rating
      Oct 16Yahoo FinanceEWTX
      William Blair initiates Edgewise Therapeutics stock with outperform rating
      Oct 16Investing.comEWTX
      Does Edgewise Therapeutics’ (EWTX) HFpEF Expansion Quietly Redefine Its Core Cardiovascular Strategy?
      Oct 15Yahoo FinanceEWTX
      H.C. Wainwright reiterates Edgewise Therapeutics stock rating at buy
      Oct 14Investing.comEWTX
      Analysts Are Bullish on These Healthcare Stocks: Argenx Se (ARGX), Edgewise Therapeutics (EWTX)

      Detailed price information for Edgewise Therapeutics Inc (EWTX-Q) from The Globe and Mail including charting and trades.

      Oct 9The Globe and MailARGXEWTX
      Edgewise doses first patient in heart failure trial
      Oct 8Investing.comEWTX
      Edgewise Therapeutics (EWTX) Sets EDG 7500 Focus Call, Is It Still 20% Below Fair Value?
      Oct 3Yahoo FinanceEWTX
      Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
      Oct 1Yahoo FinanceEWTX
      Analysts Are Bullish on These Healthcare Stocks: Prime Medicine, Inc. (PRME), Edgewise Therapeutics (EWTX)

      Tipranks Press Release.

      Sep 26The Globe and MailEWTXPRME
      Edgewise Therapeutics Could Benefit From Differentiated EDG-7500 Profile, Oppenheimer Says
      Sep 25Yahoo FinanceEWTX
      Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Lexeo Therapeutics, Inc. (LXEO) and Edgewise Therapeutics (EWTX)

      Detailed price information for Lexeo Therapeutics Inc (LXEO-Q) from The Globe and Mail including charting and trades.

      Sep 24The Globe and MailELDNEWTXLXEO
      Analysts Conflicted on These Healthcare Names: Edgewise Therapeutics (EWTX), Vertex Pharmaceuticals (VRTX) and Amgen (AMGN)

      Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

      Sep 24The Globe and MailEWTX
      Edgewise's EDG-7500 Mechanism Lends Confidence, RBC Says

      Edgewise Therapeutics' (EWTX) EDG-7500 mechanism reveal accounts for strong clinical showing, lendin

      Sep 23Yahoo FinanceEWTX
      Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 - Slideshow (NASDAQ:EWTX) 2026-09-22
      Sep 22Seeking AlphaEWTX
      Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy - Slideshow (NASDAQ:EWTX) 2026-06-17

      2026-06-17. The following slide deck was published by Edgewise Therapeutics, Inc.

      Sep 22Seeking AlphaEWTX
      Edgewise unveils mechanism of action for heart drug EDG-7500
      Sep 22Investing.comEWTX
      Edgewise Therapeutics options flow shows lopsided call activity
      Sep 18Investing.comEWTX
      Edgewise Therapeutics stock hits all-time high at 48.41 USD
      Sep 17Investing.comEWTX
      Analysts Offer Insights on Healthcare Companies: CSL (OtherCMXHF) and Edgewise Therapeutics (EWTX)

      Detailed price information for Csl Ltd (CMXHF) from The Globe and Mail including charting and trades.

      Sep 3The Globe and MailEWTX
      Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
      Sep 2Yahoo FinanceEWTX
      Analysts Offer Insights on Healthcare Companies: CSL (OtherCMXHF) and Edgewise Therapeutics (EWTX)

      Detailed price information for Edgewise Therapeutics Inc (EWTX-Q) from The Globe and Mail including charting and trades.

      Sep 2The Globe and MailEWTX
      Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026

      Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that the CIRRUS-HCM abstract was selected for a late-breaking science presentation at the European Society of Cardiology (ESC) Congress, taking place August 28-31 in Munich, Germany. EDG-7500 is a novel, oral, selective cardiac sarcomere modulator designed to slow early contraction and improve cardiac relaxation in symptomatic HCM while preserving sys

      Aug 24Yahoo FinanceEWTX

      This is the newest page. Registered accounts read further back.